Pharma orphan disease business growth

Case Prompt

• Our client is a large pharmaceutical company with a strong business in "Orphan Disease" (orphan diseases are conditions that affect fewer than 65 per 100,000 people in Brazil).
• Historically, pharmaceutical companies have not invested significantly in Orphan Disease because it has not been cost effective to conduct research for such small populations. Due to the decline in the number of pharmaceutical blockbusters and improved regulation to make R&D cheaper for Orphan Disease, pharmaceutical companies have begun to invest more in Orphan Disease R&D over the last few years.
• Our client has hired Bain because it would like to grow its Orphan Disease business.

Case Question to Solve

• How can the client double its Orphan Disease business in 5 years?